Wilson Sonsini Goodrich & Rosati advised PrognomiQ on patent matters related to the transaction. Entities found in text but not in database. Please check and add...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Radar Therapeutics on the deal, and Wilson Sonsini Goodrich & Rosati advised Radar Therapeutics on IP matters related...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Adela on patent matters related to the transaction. Adela, Inc. announced the completion of a $48 million financing. The round included existing...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised CalciMedica on the deal. Graybug Vision, Inc. and CalciMedica Inc. announced that they have entered into a definitive merger agreement to combine the...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Good Therapeutics on the deal. Good Therapeutics, a privately held company founded to create a new class of conditionally active therapeutics, announced it...
You must be a Standard 1 Year member to access this content.
Latham & Watkins and Wilson Sonsini represented Affini-T Therapeutics, Inc. in the transaction. Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati, P.C. advised Nautilus Biotechnology, while Kirkland & Ellis LLP, working alongside Ogier, advised Arya III on the deal. Latham & Watkins...
You must be a Standard 1 Year member to access this content.
